Clinical Trials on MET Activating Mutation

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China

Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAF

United States

Solid Tumor | MET Amplification | MET Exon 14 Skipping Mutation

Korea, Republic of

Solid Tumor | C-Met Mutation-Related Tumors

China

Systemic Mast Cell Activation | KIT D816V Mutation

United States, France, United Kingdom, Italy, Germany, Belgium, Spain, Switzerland

Advanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene Alteration

United States

NSCLC | Non Small Cell Lung Cancer | Oncology | MET Gene Mutation | MET Gene Amplification

United States, Korea, Republic of, Denmark, Hong Kong, Taiwan, Spain

Non-squamous Non-small-cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | ROS1 Gene Rearrangement | MET Activating Mutation | MET Amplification

Canada

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Health Care Provider | Activating ALK Gene Mutation Negative | Activating EGFR Gene Mutation Negative | Activating ROS1 Gene Mutation Negative

United States

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib

Subjects With NSCLC With an EGFR Activating Mutation

NSCLC | Activating EGFR Mutation

Hong Kong

Factors Affecting BAT Activation in PET/CT

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States

Malignant Neoplasm | PET/CT | Fibroblast Activation Protein Inhibitor

China

Lung Cancer | Non-small Cell Lung Cancer | PD-L1 Gene Mutation | KRAS Activating Mutation

United States

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

United States, Australia

Regeneration Potential of Healthy Old Men in Terms of Satellite Cell Activation

Switzerland

Newly Diagnosed AML With FLT3 Activating Mutations

United States

Non Small Cell Lung Cancer | ALK Gene Mutation | MET Gene Mutation | EGFR Gene Mutation | ROS1 Gene Mutation

China

Quality of Life | Amputation | Balance | Muscle Activation | Sense of Control

Turkey

NSCLC | BRAF V600 Mutation | MET Exon 14 Mutation

China

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

United States, United Kingdom, Austria, France

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States, Germany, Spain, Italy, France, Canada

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | RET Gene Mutation | MET Amplification

China

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States

Cancer | Lung Cancer Metastatic | MET Gene Mutation

Korea, Republic of

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditions

United States, Canada, Korea, Republic of, Japan, Taiwan

Adenocarcinoma of Lung | EGFR Activating Mutation

Korea, Republic of

Brain Metastases | Radiotherapy | EGFR Activating Mutation

China

NSCLC | EGFR Activating Mutation

China

NSCLC Stage IV | EGFR Activating Mutation

China

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong

Lung Adenocarcinoma | EGFR Activating Mutation

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB

Hong Kong

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China

Metastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation

United States

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditions

United States

Metastatic Solid Tumor | SF3B1 Gene Mutation | Spliceosome Mutation | U2AF1 Gene Mutation | SRSF2 Gene Mutation

United States

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditions

United States, Canada

Non Small Cell Lung Cancer | KRAS Activating Mutation

United States, Spain, France, United Kingdom, Netherlands, Belgium

Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies

United States

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China

BRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditions

United States

NSCLC Patients With EGFR Activating Mutation

France

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditions

United States

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong

BRCA1 Mutation | BRCA2 Mutation

United States